Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: Effects of eculizumab

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 11, 2015, Pages 2004-2011

  van Bijnen, S T A ^a   Wouters, D ^b   van Mierlo, G J ^b   Muus, P ^a   Zeerleder, S ^b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Complement; Eculizumab; Hemoglobinuria; Neutrophils; Paroxysmal; Thrombosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ECULIZUMAB; ELASTASE; ANTICOAGULANT AGENT; COMPLEMENT COMPONENT C5; LEUKOCYTE ELASTASE; MONOCLONAL ANTIBODY; NUCLEOSOME; PEPTIDE HYDROLASE;

ADULT; AGED; ARTICLE; CELL DEATH; COMPLEMENT INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NUCLEOSOME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; THROMBOSIS; TREATMENT DURATION; VERY ELDERLY; ADOLESCENT; BLOOD; COMPLEMENT ACTIVATION; DRUG EFFECTS; ENZYMOLOGY; EXTRACELLULAR TRAP; IMMUNOLOGY; JURKAT CELL LINE; MIDDLE AGED; NEUTROPHIL; THROMBOPHILIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; COMPLEMENT ACTIVATION; COMPLEMENT C5; EXTRACELLULAR TRAPS; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; INFLAMMATION; JURKAT CELLS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; NUCLEOSOMES; PEPTIDE HYDROLASES; THROMBOPHILIA; THROMBOSIS; YOUNG ADULT;

EID: 84946554566     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13125     Document Type: Article

References (33)

1. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102: 3587-91.
2. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Gramont S, Maury S, Cahn JY, Socie G. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008; 112: 3099-106.
3. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004; 126: 133-8.
4. Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost 2007; 5: 642-5.
5. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000; 30: 103-17.
6. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348: 573-7.
7. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-8.
8. Schutgens RE, Pruissen-Peeters KA, Muus P. A cascade of thromboembolic processes in a patient with paroxysmal nocturnal haemoglobinuria terminated by treatment with eculizumab. Thromb Haemost 2011; 106: 383-5.
9. van Bijnen ST, van Rijn RS, Koljenovic S, te Boekhorst P, de Witte T, Muus P. Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab. Br J Haematol 2012; 157: 762-3.
10. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-9.
11. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-43.
12. Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socie G, Brodsky RA. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162: 62-73.
13. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 4123-8.
14. Otters EF, Zarafonitis G, Steenbergen EJ, van der Valk PG, Muus P. Rapidly evolving skin manifestations due to progressive thrombosis in a patient with paroxysmal nocturnal hemoglobinuria (PNH) resolved with prompt initiation of eculizumab. Br J Dermatol 2014; 171: 908-10.
15. Brodsky A, Mazzocchi O, Sanchez F, Khursigara G, Malhotra S, Volpacchio M. Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation. Exp Hematol Oncol 2012; 1: 26.
16. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121: 4985-96.
17. van Bijnen ST, van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012; 10: 1-10.
18. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van Mierlo GJ, Eerenberg AJ, Lammle B, Hack CE. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003; 31: 1947-51.
19. Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157-69.
20. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887-96.
21. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol 2013; 735: 155-72.
22. Chen G, Zhang D, Fuchs TA, Wagner DD, Frenette PS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood 2014; 123: 3818-27.
23. van Nieuwenhuijze AE, van Lopik T, Smeenk RJ, Aarden LA. Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 10-4.
24. Nuijens JH, Abbink JJ, Wachtfogel YT, Colman RW, Eerenberg AJ, Dors D, Kamp AJ, Strack van Schijndel RJ, Thijs LG, Hack CE. Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 1992; 119: 159-68.
25. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111:1840-7.
26. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen HU, Zurcher-Zenklusen R, Rieben R, Devay J, Hack CE, Lammle B, Wuillemin WA. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002; 30: 1722-8.
27. Ward PA. Role of C5 activation products in sepsis. ScientificWorldJournal 2010; 10: 2395-402.
28. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005; 128: 2864-75.
29. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-5.
30. van Montfoort ML, Stephan F, Lauw MN, Hutten BA, van Mierlo GJ, Solati S, Middeldorp S, Meijers JC, Zeerleder S. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol 2013; 33: 147-51.
31. Hill A, Sapsford RJ, Scally A, Kelly R, Richards SJ, Khurisgara G, Sivananthan MU, Hillmen P. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol 2012; 158: 409-14.
32. Ehrengruber MU, Geiser T, Deranleau DA. Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett 1994; 346: 181-4.
33. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-5.